In Vivo Evaluation of the Acute Systemic Toxicity of (1S,2E,4R,6R,7E,11E)-Cembratriene-4,6-diol (4R) in Sprague Dawley Rats
The tobacco cembranoid (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol (4R) interacts with nicotinic acetylcholine receptors, which results in neuroprotection against organophosphate toxicity, brain ischemia, and Parkinson’s disease. The present study is a continuation of our previous research in...
Saved in:
Published in | Nutraceuticals Vol. 2; no. 2; pp. 60 - 70 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
09.04.2022
|
Online Access | Get full text |
Cover
Loading…
Summary: | The tobacco cembranoid (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol (4R) interacts with nicotinic acetylcholine receptors, which results in neuroprotection against organophosphate toxicity, brain ischemia, and Parkinson’s disease. The present study is a continuation of our previous research in which we applied a single dose of 4R 1 h before or 24 h after exposure to diisopropylfluorophosphate (DFP) (analog of the nerve agent sarin). The 4R dose robustly decreased neuroinflammation and neuronal death at both timepoints. Here, we investigated the toxicity of a single dose of 4R in male and female Sprague Dawley (SD) rats after a subcutaneous (s.c.) injection of 6, 24, or 98 mg/kg. Body weight was not affected by 4R during the 7-day observation period. No histopathologic changes in the organs were attributed to 4R. Minor hematological and blood composition variations were detected on Day 3 in the mid- and the high-dose males, but these were resolved by Day 8. At the area of the s.c. injection site, alopecia and dry skin were detected in both the 4R-treated males and females and in the female controls. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author Contributions: Conceptualization, P.A.F., N.S., O.R.P. and V.A.E.; methodology, P.A.F. and N.S.; validation, N.S.; formal analysis, P.A.F., N.S. and O.R.P.; investigation, P.A.F., N.S., O.R.P. and V.A.E.; data curation, N.S. and O.R.P.; writing—original draft preparation, P.A.F., N.S. and O.R.P.; writing—review and editing, Y.F.-A.; visualization, N.S.; supervision, N.S. and P.A.F.; project administration, P.A.F. and N.S.; funding acquisition, P.A.F. and N.S. All authors have read and agreed to the published version of the manuscript. |
ISSN: | 1661-3821 1661-3821 |
DOI: | 10.3390/nutraceuticals2020005 |